INTRODUCTION {#s1}
============

Sarcopenia is an advanced age-related loss of skeletal muscle mass as well as loss of its function, which limits the independence living and quality of life, thereby it underlies morbidity and mortality in elderly individuals \[[@R1], [@R2]\]. Sarcopenia also reduces the amount of metabolically active tissue; thus, it increases the risk for metabolic diseases \[[@R3]\]. Initiation of sarcopenia involves complex processes that are controlled by both extrinsic and intrinsic factors \[[@R3], [@R4]\], many of which converge on a decline in the ability of muscle stem cells (satellite cells) to replace unhealthy muscle fibers during aging \[[@R5]-[@R7]\]. Although the mechanism that causes sarcopenia are largely unknown, a progressive decline in anabolism mostly due to a reduction in protein synthesis with an increase of catabolism mainly due to an enhanced activation of pathways like apoptosis, initiate sarcopenia \[[@R2]\]. Apoptosis is essential for organ development, tissue homeostasis, and the elimination of defective cells in multi-cellular organisms; however, accelerated apoptosis in skeletal muscle is a potential mechanism of sarcopenia \[[@R8]-[@R13]\]. Different apoptotic stimuli such as oxidative stress, calcium, and TNF-α, may be seen as initiators of the apoptotic signaling in skeletal muscle during aging \[[@R8], [@R9], [@R14]\].

MicroRNAs (miRNAs) are a class of small noncoding RNAs that regulate gene expression at the posttranscriptional level. These noncoding RNAs have recently emerged as crucial regulators of aging process \[[@R15]-[@R17]\]. Emerging evidence has shown alteration in miRNA expression profile in the skeletal muscles of both human and mouse during aging \[[@R18]-[@R25]\]. For example, elevated let-7 family members in skeletal muscle contribute to reduced cellular proliferation and regenerative capacity in aged human \[[@R22]\]. Aging alters the expression of 57 miRNAs in mouse quadriceps muscles and few of them are associated with reduced cell proliferation and favored the terminal differentiation of myogenic precursor \[[@R20]\]. Further-more, resistance exercise, caloric restriction, or nutrientrelated hormones such as the adipokine leptin reverse the expression of age-regulated miRNAs \[[@R18], [@R21], [@R26]\]. Interestingly, it has been shown that miR-210 can mediate hypoxia-induced apoptosis of neuroblastoma cells by targeting expression of the anti-apoptotic protein Bcl-2 gene \[[@R27]\]. The above studies suggest the possibility that dysregulation of miRNAs in skeletal muscle during aging may induce sarcopenia by activating catabolic pathways, including apoptosis. However, no study to date has demonstrated a role for miRNA in skeletal muscle apoptosis, especially during aging. In the current study, we show that aging dysregulates many miRNAs in skeletal muscle, including the highly downregulated miRNA miR-434-3p that inhibits apoptosis by targeting eIF5A1 that promote apoptosis by the intrinsic mitochondrial pathway.

RESULTS {#s2}
=======

Aging dysregulates microRNA expression profile in skeletal muscle {#s2_1}
-----------------------------------------------------------------

To explore the effect of aging in the regulation of miRNA expression profile in skeletal muscle, we performed a miRNA microarray screening using total RNA isolated from the gastrocnemius (GA) muscles of young and old mice. The array uncovered the induction of 117 miRNAs with the signal intensity ≥500 (the fluorescence amount of each miRNA probe is measured by a photo multiplier tube or charge-coupled device and signal scaled across the range of detection for the platform) in GA muscle (Table [1](#T1){ref-type="table"}, Fig. [1A](#F1){ref-type="fig"} and [1B](#F1){ref-type="fig"}), including the highly downregulated miRNAs (≥1.5-fold) miR-194-5p, miR-101b-3p, miR-148a-3p, miR-199b-5p, miR-335-5p, miR-127-3p, miR-379-5p, miR-541-5p, miR-382-5p, miR-329-3p, miR-299-5p and miR-434-3p, and the highly up-regulated miRNAs (≥1.5 fold), miR-146b-5p and miR-146a-5p (Fig. [1C](#F1){ref-type="fig"}). Solution hybridization and real-time PCR assays confirmed the microarray findings (Fig. [2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"}). The small nuclear RNA U6, control, and a normalizer for miRNAs, was relatively unchanged and that excluded the possibility of artifactual changes in miRNA recovery.

###### Differentially regulated miRNAs in the GA muscle of aging mouse

  No   miRNA               Young          Old            Log~2~   No    miRNAs              Young          Old            Log~2~
  ---- ------------------- -------------- -------------- -------- ----- ------------------- -------------- -------------- --------
  1    miR-146b            410            1134           1.88     35    [let-7f]{.ul}       [35689]{.ul}   [30911]{.ul}   −0.2
  2    miR-146             2997           8074           1.61     36    [let-7e]{.ul}       [20397]{.ul}   [19144]{.ul}   −0.2
  3    miR-155             448            1338           1.28     37    [let-7d]{.ul}       [31845]{.ul}   [27066]{.ul}   −0.21
  4    miR-29b             345            626            1.16     38    [let-7a]{.ul}       [38019]{.ul}   [31797]{.ul}   −0.23
  5    miR-223             531            1646           0.99     39    [miR-30d]{.ul}      8127           [10391]{.ul}   −0.23
  6    miR-671             384            565            0.74     40    [miR-30b]{.ul}      [29922]{.ul}   [22576]{.ul}   −0.23
  7    miR-705             4676           8084           0.71     41    [let-7c]{.ul}       [32084]{.ul}   [25550]{.ul}   −0.25
  8    [miR-21]{.ul}       [10838]{.ul}   [19006]{.ul}   0.49     42    [let-7b]{.ul}       [29276]{.ul}   [24279]{.ul}   −0.25
  9    miR-203             350            661            0.48     43    [miR-486]{.ul}      [10521]{.ul}   7839           −0.27
  10   miR-221             962            862            0.35     44    [let-7g]{.ul}       [26308]{.ul}   [23201]{.ul}   −0.28
  11   [miR-709]{.ul}      [29237]{.ul}   [33168]{.ul}   0.29     45    [miR-16]{.ul}       [13343]{.ul}   [12570]{.ul}   −0.28
  12   miR-92              1753           3888           0.28     46    [let-7i]{.ul}       [20275]{.ul}   [17125]{.ul}   −0.31
  13   miR-29c             2183           3688           0.26     47    miR-133a\*          1493           956            −0.31
  14   miR-98              3911           6513           0.19     48    [miR-125b]{.ul}     [20431]{.ul}   [19224]{.ul}   −0.31
  15   miR-224             284            500            0.11     49    [miR-30a-5p]{.ul}   [11201]{.ul}   [12191]{.ul}   −0.32
  16   miR-805             3315           6839           0.1      50    miR-451             6331           3093           −0.34
  17   miR-222             711            546            0.08     51    miR-139             1117           934            −0.34
  18   miR-15b             2903           4074           0.05     52    miR-185             3866           4299           −0.35
  19   [miR-29a]{.ul}      [28014]{.ul}   [26006]{.ul}   0.03     53    miR-10b             4182           3948           −0.35
  20   [miR-133b]{.ul}     [40419]{.ul}   [33589]{.ul}   0.02     54    miR-191             6182           7454           −0.36
  21   miR-126-5p          2498           2630           0.01     55    [miR-24]{.ul}       9958           [11637]{.ul}   −0.4
  22   [miR-23b]{.ul}      [21187]{.ul}   [29118]{.ul}   −0.06    56    [miR-150]{.ul}      [10549]{.ul}   6830           −0.4
  23   [miR-23a]{.ul}      [36640]{.ul}   [28636]{.ul}   −0.07    57    miR-214             8430           5777           −0.41
  24   miR-361             1776           2579           −0.08    58    miR-103             3167           2176           −0.49
  25   [miR-1]{.ul}        [59283]{.ul}   [53604]{.ul}   −0.08    59    [miR-27b]{.ul}      [20914]{.ul}   [14373]{.ul}   −0.5
  26   [miR-26b]{.ul}      [28063]{.ul}   [26507]{.ul}   −0.09    60    [miR-27a]{.ul}      [20998]{.ul}   [13352]{.ul}   −0.52
  27   [miR-133a]{.ul}     [34591]{.ul}   [27564]{.ul}   −0.1     61    [miR-195]{.ul}      [16713]{.ul}   [11172]{.ul}   −0.53
  28   [miR-125a]{.ul}     [13997]{.ul}   [16139]{.ul}   −0.1     62    [miR-199a\*]{.ul}   [13393]{.ul}   [10549]{.ul}   −0.53
  29   miR-10a             5599           5923           −0.11    63    miR-22              7043           6474           −0.56
  30   [miR-26a]{.ul}      [41407]{.ul}   [36396]{.ul}   −0.11    64    [miR-145]{.ul}      [11134]{.ul}   8288           −0.62
  31   [miR-30c]{.ul}      [16433]{.ul}   [21901]{.ul}   −0.12    65    miR-107             3321           2128           −0.65
  32   miR-132             500            554            −0.15    66    [miR-422b]{.ul}     [12684]{.ul}   7357           −0.66
  33   miR-30a-3p          1703           2266           −0.17    67    miR-20a             1461           806            −0.67
  34   [miR-126-3p]{.ul}   [42474]{.ul}   [32921]{.ul}   −0.19    68    miR-15a             2152           1662           −0.69
  34   miR-17-5p           520            420            −0.7     94    miR-181a            3521           1470           −1.14
  36   miR-674             633            416            −0.7     95    miR-199a            994            405            −1.2
  37   miR-320             5549           3168           −0.72    96    miR-62101a          1142           524            −1.22
  38   miR-676             701            326            −0.73    97    miR-72630           1528           877            −1.25
  39   [miR-206]{.ul}      [30292]{.ul}   [16791]{.ul}   −0.76    98    miR-36564           500            400            −1.29
  40   miR-151             973            634            −0.76    99    miR-30e65           1651           836            −1.29
  41   miR-762             6082           3620           −0.78    100   miR-690             2803           1669           −1.3
  42   miR-181b            1882           1210           −0.78    101   miR-322             773            291            −1.34
  43   miR-143             9802           5554           −0.79    102   miR-424             3305           1568           −1.38
  44   miR-25              4761           2932           −0.8     103   miR-128b            1989           1114           −1.44
  45   miR-342             1915           970            −0.82    104   miR-128a            2230           885            −1.48
  46   miR-378             988            459            −0.85    105   [miR-689]{.ul}      [17376]{.ul}   5739           −1.49
  47   miR-152             4130           2123           −0.86    106   miR-194             510            184            −1.5
  48   miR-130a            627            497            −0.87    107   miR-101b            995            366            −1.5
  49   miR-140\*           1250           683            −0.89    108   miR-148a            975            367            −1.56
  50   miR-28              1060           493            −0.92    109   miR-199b            800            213            −1.59
  51   miR-106b            598            293            −0.95    110   miR-335             720            210            −2.32
  52   miR-99b             3513           1699           −0.98    111   miR-127             1989           282            −2.33
  53   let-7d\*            527            267            −1       112   miR-379             2765           500            −2.48
  54   miR-328             652            300            −1       113   miR-541             557            137            −2.55
  55   miR-99a             5591           2684           −1.01    114   miR-382             729            116            −3.12
  56   miR-100             5263           2899           −1.03    115   miR-329             1551           93             −3.57
  57   miR-499             1377           901            −1.04    116   miR-299             1767           92             −3.97
  58   miR-181d            559            269            −1.05    117   miR-434-3p          1767           154            −4.08
  59   miR-149             3221           1683           −1.06                                                            

Underlines indicate differentially regulated miRNAs at signal intensities \>10,000.

![Aging alters miRNA expression profile in skeletal muscle\
(**A** and **B**) Total RNA was isolated from the skeletal muscles from three-month-old young control and 26-month-old aging mice and used in miRNA microarray analyses to determine the expression levels of mouse miRNAs. Data on the scatter plot shows log10-transformed signal intensities for each probe labeled with Cy3 (young) and Cy5 (aging) mice (**A**). The heat map shows miRNAs significantly differentially expressed in skeletal muscle from aging mice (**B**). Each dot represents one miRNA probe. (**C**) Differentially-regulated (≥ 1.5 fold) age-related miRNAs.](aging-09-1012-g001){#F1}

![Validation of aging associated miRNA expression profile\
(**A** and **B**) A portion of RNA used in the microarray was used in qPCR (**A**) and in a separate experiment by solution hybridization technique with 5\' biotin-labeled miRNAs (**B**) to confirm the expression level of miRNAs that were differentially regulated ≥1.5-fold in the microarray. U6 served as both loading control and normalizer. Gel pictures are representative of three independent experiments. Each bar indicates mean ± SEM (n = 3). White and black bars indicate the levels of miRNA measured by microarray and qPCR, respectively.](aging-09-1012-g002){#F2}

Identification of predicted biological pathways of dysregulated-miRNAs in aging skeletal muscle {#s2_2}
-----------------------------------------------------------------------------------------------

To determine predicted biological pathways of miRNAs differentially regulated (≥1.5 fold) in the aging skeletal muscle, we used DIANA miRPath v 3.0 software. The threshold p values for the pathway and MicroT were set to 0.05 and 0.8, respectively. The KEGG pathway in DIANA miRPath identified 87 (Table [2](#T2){ref-type="table"}) biological pathways, including, 20 pathways for up-regulated miRNAs and 67 pathways for down-regulated miRNAs. Among those pathways, 7 (up-regulated miRNAs) and 25 (down-regulated miRNAs) pathways were associated with skeletal muscle functions (Table [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}). According to gene ontology, there are 24 genes involved in the seven pathways, whereas 785 genes are involved in 25 pathways. The DIANA miRPath provided 8 predicted skeletal muscle pathways, including apoptosis for the highly downregulated miRNA-434-3p (Table [5](#T5){ref-type="table"}).

###### Predicted biological pathways linked to differentially regulated miRNAs (\>1.5-fold) in the GA muscle of aging mouse

  No   KEGG pathway                                      p-value        Genes    miRNAs
  ---- ------------------------------------------------- -------------- -------- --------
  1    **PI3K-Akt signaling pathway**                    **7.21E-12**   **90**   **13**
  2    Pathways in cancer                                1.79E-10       88       13
  3    **MAPK signaling pathway**                        **1.90E-20**   **82**   **14**
  4    HTLV-I infection                                  6.23E-12       77       14
  5    **Regulation of actin cytoskeleton**              **8.73E-13**   **65**   **14**
  6    **Focal adhesion**                                **8.92E-16**   **63**   **12**
  7    **Wnt signaling pathway**                         **3.09E-23**   **59**   **13**
  8    Transcriptional misregulation in cancer           2.36E-11       58       14
  9    Protein processing in endoplasmic reticulum       3.17E-12       53       12
  10   Axon guidance                                     5.07E-23       52       13
  11   Endocytosis                                       5.35E-05       51       13
  12   Dopaminergic synapse                              2.95E-15       48       10
  13   **Ubiquitin mediated proteolysis**                **1.08E-10**   **45**   **12**
  14   Chemokine signaling pathway                       0.000375       45       14
  15   **Insulin signaling pathway**                     **3.53E-11**   **43**   **13**
  16   Calcium signaling pathway                         0.000783       43       12
  17   Hepatitis B                                       1.72E-06       41       14
  18   Neurotrophin signaling pathway                    9.78E-12       40       13
  19   Tuberculosis                                      0.003419       40       13
  20   Glutamatergic synapse                             3.53E-11       39       11
  21   T cell receptor signaling pathway                 1.38E-11       37       14
  22   Cholinergic synapse                               7.49E-07       36       11
  23   RNA transport                                     0.021696       35       13
  24   Retrograde endocannabinoid signaling              1.20E-07       34       9
  25   ErbB signaling pathway                            1.43E-14       33       12
  26   Oocyte meiosis                                    9.73E-05       32       11
  27   **Cell cycle**                                    **0.004448**   **32**   **13**
  28   Prostate cancer                                   8.27E-12       31       13
  29   Osteoclast differentiation                        7.19E-05       31       11
  30   Serotonergic synapse                              0.005448       30       11
  31   Chagas disease (American trypanosomiasis)         2.70E-05       29       13
  32   Hepatitis C                                       0.027024       29       13
  33   Spliceosome                                       0.027549       29       11
  34   Chronic myeloid leukemia                          4.29E-10       27       13
  35   Hypertrophic cardiomyopathy (HCM)                 1.32E-08       27       8
  36   Renal cell carcinoma                              8.82E-08       27       12
  37   GnRH signaling pathway                            5.84E-07       27       13
  38   Melanogenesis                                     7.49E-05       27       11
  39   GABAergic synapse                                 0.004621       27       9
  40   Long-term potentiation                            8.27E-12       26       11
  41   Small cell lung cancer                            6.84E-07       26       13
  42   Dilated cardiomyopathy                            3.62E-06       26       8
  43   **Apoptosis**                                     **3.24E-05**   **26**   **12**
  44   mRNA surveillance pathway                         0.001512       26       12
  45   Pancreatic cancer                                 2.37E-08       25       11
  46   Melanoma                                          2.80E-08       25       11
  47   B cell receptor signaling pathway                 1.52E-07       25       13
  48   **TGF-beta signaling pathway**                    **4.55E-05**   **25**   **12**
  49   **p53 signaling pathway**                         **3.29E-07**   **23**   **10**
  50   **Adherens junction**                             **3.18E-05**   **23**   **11**
  51   Arrhythmogenic right ventricular cardiomyopathy   0.000115       23       10
  52   Progesterone-mediated oocyte maturation           0.000564       23       11
  53   Amphetamine addiction                             0.00381        23       12
  54   **mTOR signaling pathway**                        **1.20E-07**   **22**   **11**
  55   **VEGF signaling pathway**                        **1.20E-07**   **22**   **11**
  56   Glioma                                            6.54E-05       22       12
  57   Bacterial invasion of epithelial cells            7.19E-05       21       8
  58   Salmonella infection                              0.000308       21       9
  59   **Phosphatidylinositol signaling system**         **0.005448**   **21**   **10**
  60   **Adipocytokine signaling pathway**               **4.03E-05**   **20**   **11**
  61   Gastric acid secretion                            0.001232       20       9
  62   Non-small cell lung cancer                        2.32E-06       19       11
  63   Colorectal cancer                                 0.000274       19       11
  64   **Gap junction**                                  **0.00222**    **19**   **12**
  65   Endometrial cancer                                1.79E-06       18       10
  66   **Lysine degradation**                            **3.31E-07**   **17**   **9**
  67   Acute myeloid leukemia                            3.07E-05       17       13
  68   Amyotrophic lateral sclerosis (ALS)               9.65E-05       17       11
  69   **Inositol phosphate metabolism**                 **0.000552**   **17**   **10**
  70   RIG-I-like receptor signaling pathway             0.01547        17       13
  71   Fc epsilon RI signaling pathway                   0.022008       17       10
  72   **Hedgehog signaling pathway**                    **2.88E-05**   **16**   **8**
  73   **Calcium reabsorption**                          **0.005096**   **16**   **9**
  74   **Type II diabetes mellitus**                     **0.00052**    **15**   **8**
  75   Circadian rhythm                                  5.32E-08       14       7
  76   Bladder cancer                                    0.001543       13       9
  77   Basal transcription factors                       0.002387       13       11
  78   **Sphingolipid metabolism**                       **0.028141**   **13**   **7**
  79   Aldosterone-regulated sodium reabsorption         0.001227       12       11
  80   Vasopressin-regulated water reabsorption          0.045885       12       6
  81   Dorso-ventral axis formation                      1.52E-07       10       10
  82   **Alanine, aspartate and glutamate metabolism**   **0.016589**   **10**   **7**
  83   Prion diseases                                    3.96E-10       7        7
  84   Proximal tubule bicarbonate reclamation           0.004531       7        5
  85   Taurine and hypotaurine metabolism                0.004447       4        3
  86   D-Glutamine and D-glutamate metabolism            0.000519       3        3
  87   **Biotin metabolism**                             **0.00381**    **1**    **1**

Bold indicates skeletal muscle specific pathways.

###### Predicted biological pathways controlled by up-regulated miRNAs

  No   KEGG pathway                           p-value    Genes   miRNAs
  ---- -------------------------------------- ---------- ------- --------
  1    MAPK signaling pathway                 0.028946   6       2
  2    NF-kappa B signaling pathway           3.96E-05   4       2
  3    Apoptosis                              0.010616   4       2
  4    Toll-like receptor signaling pathway   0.001913   3       2
  5    VEGF signaling pathway                 0.01676    3       2
  6    ECM-receptor interaction               0.004068   2       2
  7    TGF-beta signaling pathway             0.029883   2       2

###### Predicted biological pathways controlled by downregulated miRNAs

  No   KEGG pathway                                  p-value    Genes   miRNAs
  ---- --------------------------------------------- ---------- ------- --------
  1    PI3K-Akt signaling pathway                    7.21E-12   90      13
  2    MAPK signaling pathway                        1.90E-20   82      14
  3    Regulation of actin cytoskeleton              8.73E-13   65      14
  4    Focal adhesion                                8.92E-16   63      12
  5    Wnt signaling pathway                         3.09E-23   59      13
  6    Ubiquitin mediated proteolysis                1.08E-10   45      12
  7    Insulin signaling pathway                     3.53E-11   43      13
  8    Cell cycle                                    0.004448   32      13
  9    Apoptosis                                     3.24E-05   26      12
  10   TGF-beta signaling pathway                    4.55E-05   25      12
  11   Adherens junction                             3.18E-05   23      11
  12   p53 signaling pathway                         3.29E-07   23      10
  13   mTOR signaling pathway                        1.20E-07   22      11
  14   VEGF signaling pathway                        1.20E-07   22      11
  15   Phosphatidylinositol signaling system         0.005448   21      10
  16   Adipocytokine signaling pathway               4.03E-05   20      11
  17   Gap junction                                  0.00222    19      12
  18   Inositol phosphate metabolism                 0.000552   17      10
  19   Lysine degradation                            3.31E-07   17      9
  20   Calcium reabsorption                          0.005096   16      9
  21   Hedgehog signaling pathway                    2.88E-05   16      8
  22   Type II diabetes mellitus                     0.00052    15      8
  23   Sphingolipid metabolism                       0.028141   13      7
  24   Alanine, aspartate and glutamate metabolism   0.016589   10      7
  25   Biotin metabolism                             0.00381    1       1

###### Predicted biological pathways controlled by miR-434-3p

  No   KEGG pathway                                 p-value    Genes   miRNAs
  ---- -------------------------------------------- ---------- ------- --------
  1    Fatty acid degradation                       2.65E-10   1       1
  2    Fatty acid metabolism                        2.58E-06   1       1
  3    Sphingolipid metabolism                      0.002379   3       1
  4    MAPK signaling pathway                       0.002885   10      1
  5    N-Glycan biosynthesis                        0.003339   3       1
  6    Valine, leucine and isoleucine degradation   0.005375   1       1
  7    Apoptosis                                    0.010371   3       1
  8    PI3K-Akt signaling pathway                   0.021814   7       1

eIF5A1 is a target mRNA of miR-434-3p {#s2_3}
-------------------------------------

Because miR-434-3p is the highly downregulated miRNA in the skeletal muscle of aging mice, we searched for predicted miR-434-3p target genes using the public database of RNA22 \[[@R28]\]. Interestingly, the database listed eIF5A1 as one of the potential targets of miR-434-3p. Moreover, eIF5A1 has a conservative miR-434-3p seed sequence in its 3′-UTR (Fig. [3A](#F3){ref-type="fig"}). These data provided a strong rationale to test the possibility that eIF5A1 may be a downstream target of miR-434-3p. First, we tested whether miR-434-3p transcriptionally or post-transcriptionally suppresses endogenous eIF5A1 expression. To test this possibility, we transfected myotubes with NS-miR (non-specific miRNA) or miR-434-3p mimic. Myotubes carrying miR-434-3p showed overexpression of miR-434-3p by approximately three-fold (Fig. [3B](#F3){ref-type="fig"}). Enforced expression of miR-434-3p significantly decreased eIF5A1 mRNA levels (Fig. [3C](#F3){ref-type="fig"}). The reduction in eIF5A1 mRNA levels was concomitant with a decrease in eIF5A1 protein levels (Fig. [3D](#F3){ref-type="fig"}), suggesting that miR-149 predominantly suppresses eIF5A1 mRNA levels. Subsequently, we tested that whether eIF5A1 3′UTR is directly targeted by miR-434-3p. A reporter construct containing the luciferase gene fused to the eIF5A1 3′-UTR (luc-eIF5A1-3′-UTR) or luciferase gene fused to the mutated eIF5A1 3′-UTR (luc-eIF5A1-3′-UTR-M) (Fig. [3E](#F3){ref-type="fig"}) was co-transfected with NS-miR or miR-434-3p mimics with or without miR-434-3p antagomir into myotubes. As shown in Fig. [3F](#F3){ref-type="fig"}, while cells transfected with luc-eIF5A1-3′-UTR alone or co-transfected with NS-miR had luciferase activity, cells co-transfected with miR-434-3p mimics displayed a reduction in luciferase activity significantly. The transfection of miR-434-3p antagomir along with luc-eIF5A1-3′-UTR and miR-434-3p mimics restored the luciferase activity. Surprisingly, miR-434-3p and eIF5a1 3′UTR binding is only by six base pair matching that may cause a weaker interaction. Therefore, we mutated the miR-434-3p binding site on eIF5A1-3′-UTR to determine whether eIF5A1 is a direct target of miR-434-3p. Our luciferase assay experiments with mutations in the binding sites clearly confirmed eIF5a1 is a direct target mRNA of miR-434-3p (Fig. [3F](#F3){ref-type="fig"}). Overall, these data provide experimental evidence that eIF5A1 is a direct target gene of miR-434-3p.

![eIF5A1 is a target mRNA of miR-434-3p\
(**A**) Sequence alignment of putative miR-434-3p targeting site in the 3′-UTR of eIF5A1 shows high levels of complementarity. (**B**-**D**) Myotubes were transfected with miR-434-3p mimetic or NS-mimetic. miR-434-3p overexpression was determined by qPCR assay (B). U6 served as a normalizer. eIF5A1 mRNA levels were analyzed 24 h after transfection by qPCR (**C**) and eIF5A1 protein levels were analyzed 36 h after transfection by Western blot (**D**). (**E**) Sequence information represents the site directed mutagenesis on the 3′UTR of eIF5A1. Red letters indicate mutated nucleotide and arrows indicate nucleotide position. (**F**) The eIF5A1 3′-UTR--luciferase construct or eIF5A1 3′-UTR mutated--luciferase construct were co-transfected with NS-mimetic, miR-434-3p mimetic, miR-434-3p antagomir or SC-miR. Forty-eight hours after transfection, cells were collected, and then firefly luciferase activities were estimated and normalized to Renilla luciferase activities. Each bar indicates mean ± SEM (n = 3). \*P \< 0.05 vs. NS-miR. Gel pictures are representative of three independent experiments.](aging-09-1012-g003){#F3}

miR-434-3p protects myocytes from apoptosis through eIF5A1 {#s2_4}
----------------------------------------------------------

Previous studies have shown that eIF5A1 promotes apoptosis in a variety of cells \[[@R29]-[@R32]\]. Our prediction pathway analysis for miR-434-3p identified apoptosis as one of the skeletal muscle-specific pathways. Because eIF5A1 is a direct downstream target of miR-434-3p, we sought to determine if modulation of miR-434-3p would control apoptosis through eIF5A1 in myotubes. TPEN (a potent inducer of apoptosis) has been shown to induce apoptosis in myocytes \[[@R33]\]. Myotubes were transfected with miR-434-3p mimics or NS-miR for 36 h before treatment with TPEN for 24 h. Our data show that myotubes transfected with NS-miRNA before TPEN exposure had no protection against TPEN-induced apoptosis (Fig. [4A](#F4){ref-type="fig"}). In contrast, myotubes transfected with miR-434-3p mimics before TPEN treatment had an about 70% reduction in the percentage of apoptotic cells compared with myotubes transfected with NS-miRNA mimics. The transfection of miR-434-3p antagomir along with miR-434-3p mimics restored the TPEN-induced myotubes death (Fig. [4A](#F4){ref-type="fig"}). Western blot analysis indicated that TPEN-treated myotubes displayed an increased levels of eIF5A1 protein whereas myotubes transfected with NS-miR or myotubes that were not transfected had no effect on myotubes survival. On the other hand, transfection of myotubes with miR-434-3p mimics strongly reduced eIF5A1 protein levels and the cotransfection of myotubes with miR-434-3p antagomir reinstated eIF5A1 protein levels (Fig. [4B](#F4){ref-type="fig"}). To further confirm the role of miR-434-3p in apoptosis, we used staurosporine (Stsp), a well-known transcription inhibitors, has been shown to induce apoptosis in several cell types including myocytes \[[@R33], [@R34]\]. While myotubes treated with Stsp had a higher percentage of death, transfection of those myotubes with miR-434-3p mimic increased the proportion of myotubes survival and co-transfection of myotubes with miR-434-3p antagomir reversed the effect of miR-434-mimic (Fig. [4C](#F4){ref-type="fig"}). Furthermore, loss of myotubes survival due to Stsp treatment correlated with a significant increase in the levels of eIF5A1 protein. Such altered expression of elF5A1 was reduced when those myotubes were transfected with miR-434-3p antagomir (Fig. [4D](#F4){ref-type="fig"}). In addition, knockdown of eIF5A1 by siRNA in myotubes significantly reduced the TPEN or Stsp -induced cell death (Fig. [4E](#F4){ref-type="fig"}), suggesting that eIF5A1 is directly responsible for the TPEN or Stsp-induced apoptotic effect. Furthermore, we found that GA muscle from aging mice displayed lower expression levels of miR-434-3p when compared to that in the GA muscle of young mice (Fig. [4F](#F4){ref-type="fig"}). In contrast, the levels of eIF5A1 mRNA and protein were higher in the GA muscle of aging mice when compared to that in the GA muscle of young mice (Fig. [4F](#F4){ref-type="fig"}). These data confirm that miR-434-3p protects myocyte from apoptosis induced by different apoptotic stimuli *via* eIF5A1 and a negative correlation between the expression of miR-434-3p and eIF5A1 in aging muscle.

![miR-434-3p protects apoptosis through eIF5A1\
Myotubes were transfected with NS-mimetic, miR-434-3p mimetic with or without miR-434-3p antagomir or no transfection for 24 h followed by eight hours TPEN (100 μM) or Stps (1 μM) incubation. (**A** and **B**) Apoptosis (%) was measured by MTT assay in TPEN treated and non-treated myotubes (**A**) and the expression of eIF5A1 protein levels were determined by western blot (**B**). (**C** and **D**) Apoptosis (%) was measured by MTT assay in Stps treated and non-treated myotubes (**C**) and the expression of eIF5A1 protein levels were determined by western blot (**D**). (**E**) Myotubes were transfected with non-specific siRNA (NS-siRNA) or eIF5A1 siRNA for 24 h followed by eight hours TPEN (100 μM) or Stps (1 μM) incubation. Apoptosis (%) was measured by MTT assay. (**F**) miR-434-3p and eIF5A1 levels in young and aging GA muscles were determined by solution hybridization and western blot methods, respectively. U6 and GAPDH were served as loading controls for miR-434-3p and eIF5A1, respectively. Gel pictures are representative of three independent experiments. Each bar indicates mean ± SEM (n = 3). \*, p\< 0.05 vs. control; ϕ, p \<0.05 vs. NS-miR or NS-siRNA; δ, p \< 0.05 vs. mimic.](aging-09-1012-g004){#F4}

Overexpression of miR-434-3p reduces activation of caspases 3, 8, and 9 in myotubes {#s2_5}
-----------------------------------------------------------------------------------

To determine whether miR-434-3p-regulated apoptosis involves inhibition of activation of caspases, the effects of their over-expression on the activation of executioner caspase-3 as well as initiator caspases −8 and −9 were examined in myotubes over a period of 24 h. All three caspases were activated in response to TPEN or Stps treatment; however, caspase 3 activity was dramatically higher when compared to caspases 8 and 9, especially in Stps treated myotubes (Fig. [5A](#F5){ref-type="fig"} and [B](#F5){ref-type="fig"}). Myotubes transfected with miR-434-3p mimic significantly suppressed all three caspases activities, and the cotransfection of miR-434-antagomir restored the TPEN or Stps-induced caspases activities whereas myotubes transfected with NS-miR had no effect on all three caspases activities in response to TPEN or Stps treatment (Fig. 6A and B). One of the earliest events in the progression of apoptosis is the dissipation of the mito-chondrial membrane potential (∆ψm). Our data in Fig [5C](#F5){ref-type="fig"} and [D](#F5){ref-type="fig"} showed suppression of caspases 3, 8 and 9 activities by miR-434-3p, suggesting the possibility that miR-434-3p may maintain Δψm. JC-1 is a different cationic dye has been used to measure the collapse of the electrochemical gradient across the mitochondrial membrane \[[@R34], [@R35]\]. In normal untreated myotubes, JC-1 is present as a red fluorescent aggregate in mito-chondria, and in the green fluorescent monomeric form in the cytosol in myotubes. Upon the treatment with TPEN or Stsp, there is a dissipation of the ∆ψm indicated by the increase in staining in the green filter (530 nm) and a decrease in staining in the red filter (590 nm) in myotubes. Quantification of the fluorescent intensities indicated that myotubes treated with TPEN or Stsp significantly decreased the ∆ψm index while myotubes transfected with miR-434-3p mimic reversed the scenario; in contrast, the cotransfection of antagomir restored the effect of TPEN and Stsp in ∆ψm (Fig. [5C](#F5){ref-type="fig"}). These data suggest that the diminished depolarization of mitochondrial membrane potential of myotubes in response to TPEN and Stsp may be due to suppression of apoptosis by miR-434-3p through eIF5A1.

![miR-434-3p protects myotubes from caspase activation and loss of mitochondrial membrane potential\
Myotubes were transfected with NS-mimetic, miR-434-3p mimetic, miR-434-3p antagomir or no transfection for 24 h followed by eight hours TPEN (100 μM) or Stps (1 μM) incubation. (**A** and **B**) Enzymatic activities of caspase-3, −8 and −9 in myotubes treated with TPEN (A) and Stsp (B) were determined by caspase specific fluorogenic substrates. (**C**) Untreated (control) or treated myotubes were stained with JC-1 and observed under TRITC (590 nm) and GFP (530 nm) filters. %Δψm index represents the ratio of red to green fluorescence. Each bar indicates mean ± SEM (n = 3). \*, p \< 0.05 vs. control; ϕ, p \< 0.05 vs. NS-miR; δ, p \< 0.05 vs. mimic.](aging-09-1012-g005){#F5}

DISCUSSION {#s3}
==========

Sarcopenia is a progressive decline in skeletal muscle mass, strength, and quality during aging. Although the molecular mechanisms involved in sarcopenia development are not entirely understood, it is welldocumented that transcriptomic, proteomic and epigenetic changes during the progression of aging are the main causative factors for sarcopenia. These epigenetic changes could increase oxidative stress and *vice versa* and lead to muscle loss and function due to activation of multiple catabolic pathways, including apoptosis. The main objective of this study was to determine the effect of aging on miRNA expression profile and identify how dysregulation of a specific miRNA in aging muscle could cause the activation of the catabolic pathway(s). Using microarray analysis, we found that aging dysregulated miRNA expression profile in skeletal muscle and most of the dysregulated miRNAs are suppressed in aging muscle. Using extensive bioinformatics analysis, we identified the eukaryotic translation initiation factor 5A1 (eIF5A1) as one of the potential target genes of the most highly downregulated miRNA miR-434-3p. Overexpression or knockdown of miR-434-3p in myotubes validated eIF5A1 as a target mRNA of miR-434-3p that negatively regulated apoptosis through eIFA1. Further-more, dual-luciferase assay validation method further confirmed miR-434-3p binding site within the 3′UTR mRNA encoding eIF5A1. Interestingly, we found that skeletal muscle from aging mice downregulated of miR-434-3p expression that was negatively correlated with the levels of eIF5A1, suggesting that dysregulation of miR-434-3p in aging muscle may be responsible, in part, for the pathogenicity of sarcopenia.

In the present study, we found that aging dysregulated many miRNAs, including two upregulated and 13 downregulated (≥1.5 fold) miRNAs in skeletal muscle, suggesting diminished miRNA expressions profile in aging muscle, and this is in agreement with previous findings \[[@R19], [@R23], [@R25], [@R36]\]. The differentially expressed miRNAs in earlier studies appeared consistently in mouse skeletal muscle from our study; for example, the expression pattern of miR-146a-5p, miR-146b-5p, miR-434-3p, miR-127-3p, and miR-148a-3p are similar to previous studies. In our study, we found that miR-434-3p was the highly downregulated mRNA (4.08 fold) in the aging muscle; this is also in agreement with the previous study in which aging mice downregulates this miRNA at 5.0 fold in skeletal muscle \[[@R20]\]. This suggesting that miR-434-3p may have a crucial role in the etiology of aging. Using extensive bioinformatics analysis, we identified eIF5A1 as one of the potential target genes of miR-434-3p. We confirmed that miR-434-3p indeed suppressed eIF5A1 mRNA expression by binding on the 3′UTR of eIF5A1, as evidenced by western blot analysis and luciferase assay. Moreover, we for the first time demonstrate that aging muscle up-regulated eIF5A1 protein expression, suggesting a negative correlation in the expression levels between miR-434-3p and eIF5A1 in the aging muscle. In agreement with our findings, a previous study demonstrates that overexpression of miR-434-3p *in vivo* rat skeletal muscle post-transcriptionally suppresses eIF5A1 expression and both miR-434-3p and eIR5A1 are regulated in muscle in an opposite manner after spinal cord injury \[[@R37]\]. Although miR-434-3p was the most highly downregulated miRNA in the skeletal muscle of aged mice, the signal intensity was relatively small (1767) when compare to other miRNAs such as miR-1 (59283) and miR-126-3p (42474) as evidenced by microarray that is not a quantitative assay and signal intensity more than 500 is biologically relevant. Interestingly, our quantitative PCR assay in Figures [2A](#F2){ref-type="fig"} and [4F](#F4){ref-type="fig"} show that miR-434-3p was nearly 4-fold significantly downregulated in aging muscle when compared to that in the muscle of young mice, suggesting that aging significantly affected the expression of miR-434-3p. This significance was confirmed by solution hybridization detection (miR-434-3p) and western blot (eIF5A1). In addition, the miR-434-3p is absence in human according to miRBase 21 that limits the translational significance. Because many miRNAs can target a single mRNA, other human miRNA(s) that target eIF5A1 may have a similar role of miR-434-3p and that specific miRNA(s) may reinstate the translational significance of miR-434-3p. Overall our findings suggest that the dysregulation of the miR-434-3p/eIF5A1 pathway in aging muscle may play a role in the pathogenicity of sarcopenia.

The small protein eIF5A1 promotes the initiation and translation elongation phases of protein synthesis by transient association with 80S ribosome complex \[[@R38]-[@R41]\]. However, numerous other functions have also been identified for eIF5A, including apoptosis in a variety of cells \[[@R31], [@R32], [@R42]\]. In this study, up-regulation of eIF5A1 protein and downregulation of miR-434-3p in aging skeletal muscle suggest that miR-434-3p/eIF5A1 pathway may induce apoptosis in skeletal muscle during aging and that may be one of the epigenetic causative mechanisms for the induction of sarcopenia. Although the etiology of sarcopenia is complex and characterized by the contribution of multiple factors \[[@R43]\], there is growing evidence for a prominent role of accelerated apoptosis in sarcopenia \[[@R12], [@R43]-[@R47]\].

Previous studies identified a role for eIF5A1 in apoptosis; these studies demonstrate that siRNA-mediated suppression of eIF5A1 expression protects cells against apoptosis induced by TNF-α \[[@R30]\], Actinomycin D \[[@R31], [@R32]\], sodium nitroprusside as well as the proteasome inhibitor MG-132 \[[@R32]\]. Conversely, over-expression of eIF5A1 has been shown to induce apoptosis \[[@R31], [@R32], [@R42]\], further supporting the apoptogenic nature of eIF5A1. This study sheds some light to determine how eIF5A1 engages in apoptosis in skeletal muscle during aging. We found that eIF5A1 facilitates activation of the intrinsic mitochondrial apoptotic pathway. We demonstrate that knockdown of miR-434-3p in myotubes induced activation of caspase-3, −8 and −9, and permeabilization of the outer mitochondrial membrane along with up-regulation of eIF5A1, suggesting that loss of miR-434-3p promotes apoptosis by facilitating activation of the intrinsic mitochondrial pathway. We confirmed the above data by demonstrating that overexpression of miR-434-3p resulted in inhibition of caspase-3, −8 and −9 activations, and permeabilization of the outer mitochondrial membrane along with downregulation of eIF5A1. Oxidative damage to lipids, proteins, and DNA, especially in post-mitotic tissue like the skeletal muscle of an aged organism, may be severe and ultimately lead to apoptotic or necrotic cell death. We and others have previously shown an elevation of oxidative and apoptosis markers in skeletal muscle from aging mice \[[@R48]-[@R52]\]. Future studies should focus on determining the causal mechanism through which aging of skeletal muscles suppresses miR-434p.

METHODS {#s4}
=======

Animals {#s4_1}
-------

The Institutional Animal Care and Use Committee from the Baylor College of Medicine approved all experimental procedures. We used a total of 44 mice to complete the experiments mentioned in this study. These include three-month-old young (n=20), and 26 months old aged (n=24) male C57BL/6J mice (The Jackson Laboratory, Bar Harbor, ME). All mice were kept in a temperature-controlled room on a 12-h light/dark cycle, with a temperature of 23°C, humidity of 40--60%, and food and water ad libitum.

Cell culture {#s4_2}
------------

For in vitro studies, we used primary myoblasts isolated from young mouse hind limb muscles and cultured them to induce myotubes as described previously \[[@R53]\].

miRNA microarray analysis {#s4_3}
-------------------------

We isolated total RNA from the skeletal muscles of young and aged mice and used for microarray analysis as mentioned earlier \[[@R54], [@R55]\]. The fold difference values of altered miRNAs were converted into log~2~ scale.

Gene functional analysis {#s4_4}
------------------------

To identify the predicted biological pathways regulated by miRNAs (≥1.5-fold), we used the DIANA miRPath v2.0 Web-based computational tool with a threshold p-value of 0.05 and a MicroT threshold value of 0.8 \[[@R56]\]. miRNAs and their predicted targets were identified using the miRWalk Web-based computational tool, which provides miRNA targets from at least eight established miRNA prediction programs \[[@R57]\].

Reverse transcription and quantitative PCR (RT-qPCR) {#s4_5}
----------------------------------------------------

To validate differentially regulated miRNA data from microarray analysis, we performed miRNA RT-qPCR array as described earlier \[[@R54], [@R55]\]. To normalize mRNA and miRNA levels in qPCR, we used glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and U6, respectively.

Solution hybridization detection analysis {#s4_6}
-----------------------------------------

To confirm microarray data, we measured the expression levels of mature miRNAs by a solution hybridization detection method with mirVana miRNA and Bright-Star BioDetect kits as described previously \[[@R54]\].

Western blot {#s4_7}
------------

Western blots were performed as documented earlier \[[@R53]\]. eIF5A1 and GAPDH antibodies were purchased from Cell Signaling, Danvers, MA.

Transfection {#s4_8}
------------

Primary myoblasts were plated in 6-well plates (for immunoblot analyses) or 24-well plates (for 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide \[MTT\] assay) in medium containing 10% FBS and allowed to adhere for 24 hours. The next day, myoblast differentiation was induced for three days, and the myotubes were transfected with 30nM of miR-434-3p mimetic or the NS microRNA (miR-NS) control (miRvana; Life Technologies). For RNAi study, the myotubes were transfected with 50 pmols NS-siRNA or eIF5A1-siRNA acoording to the manufacturer protocol (SantaCruz Biotechnology, Inc). All transfections were performed with Lipofectamine RNAi MAX (Life Technologies) according to the instructions provided by the manufacturer. The microRNA mimetic or siRNA and Lipofectamine solutions were prepared in Opti-MEM I Reduced Serum Medium (Life Technologies), mixed gently, and incubated 5--10 minutes at room temperature. The lipid-complexed microRNA mimetic was added gently to the 6- or 24-well plates and incubated as indicated in each experiment. Luciferase assays were performed as described previously \[[@R55]\]. Briefly, 2.5 mg of expression vector bearing mmu--miR-149 precursor, mouse pcDNA--PARP-2, mouse pcDNA--PARP-2 without 39-UTR, 2.3 mg of pmirGLO-PARP-2--39-UTR, or 400 ng of mmu--miR-149 miRCURY LNA knockdown probe (antagomir) or scrambled probe (Exiqon, Woburn, MA) was added.

eIF5A1 3′-UTR mutagenesis {#s4_9}
-------------------------

The miR-434-3p binding sites on eIF5A1 3′UTR were mutated as we described previously \[[@R58]\] using QuikChange II site-directed mutagenesis kit (Stratagene). Briefly, the eIF5A1 3′UTR at the miR-434-3p canonical binding sites, were obtained by replacing the 5′-GCCTGUGGTTTAGG-3 consensus sequence by 5′-GCCTGTGAATTAGG-3. The eIF5A1-3′ UTR was mutagenized by site-directed mutagenesis by using the following primers: −5′-TGCTTGTGGTTTAGGTTCCC-3′ and 5′-ATCGGGGATGAGTAGGATAA −3′ for eIF5A1-3′UTR-M.

Induction of apoptosis {#s4_10}
----------------------

Apoptosis was induced in myotubes by treated with TPEN or staurosporine (Stsp) (Santa Cruz Biotechnology, Inc. Dallas, TX). Briefly, cells were treated for seven hours with TPEN (10 μM -- 100 μM) or Stsp (0.5--2 μM) to induce apoptosis. We observed that about a 50--60% cell death occurred at 100 μM TPEN or 1 μM Stsp at eight hours (data not shown) and therefore we used this concentration for further experiments.

Cell viability assay {#s4_11}
--------------------

Cell survival was measured using the standard MTT cell viability assay protocol. Briefly, primary myoblasts were plated in 24-well plates in medium containing 10% FBS and allowed to adhere for 24 hours. Then, the differentiation of primary myoblasts was induced as described previously \[[@R53]\]. After treatment of myotubes, cell viability was quantified by MTT (obtained from Sigma-Aldrich) and expressed as a percentage as mentioned earlier \[[@R59]\]. All experiments were repeated at least three times, with each experimental condition repeated at least in triplicate per experiment.

Assessment of mitochondrial membrane potential (Δψm) {#s4_12}
----------------------------------------------------

Because a decline in Δψm causes the escape of pro-apoptotic proteins that regulate both caspase-dependent and independent apoptosis from mitochondria into the cytosol, we measured Δψm as an early event in the initiation of apoptosis. After appropriate treatments of myotubes, Δψm was assessed using the cationic dye, JC-1 (5,5′, 6,6′-tetrachloro-1,1′,3,3′-tetraethyl-benzimidazolylcarbocyanine iodide). JC1 stains the healthy myotubes with bright red due to accumulation of the dye within the mitochondria whereas the dye stains the apoptotic myotubes with green because of the collapse of the mitochondrial membrane potential resulting in the dye unable to accumulate within the mitochondria. After treatment, myotubes were rinsed with PBS, followed by incubation with JC-1 reagent 1:100 at 37°C for 30 min. After rinsed myotubes twice with PBS, images were obtained using TRITC (red, 590 nm) and GFP (green, 530 nm) filters on a fluorescent microscope (Carl Zeiss). Care was taken to obtain pictures with identical exposure times, and pictures were analyzed using Carl Zeiss software. The automatic measurement program with same user defined parameters for densitometric and geometric variables was used to determine fluorescent intensity for both filters. The ratio of the sum of intensities of red over green fluorescence was identified and expressed as the Δψm index.
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